7-Ketocholesterol induces P-glycoprotein through PI3K/mTOR signaling in hepatoma cells

Biochem Pharmacol. 2013 Aug 15;86(4):548-60. doi: 10.1016/j.bcp.2013.06.006. Epub 2013 Jun 19.

Abstract

7-Ketocholesterol (7-KC) is found at an elevated level in patients with cancer and chronic liver disease. The up-regulation of an efflux pump, P-glycoprotein (P-gp) leads to drug resistance. To elucidate the effect of 7-KC on P-gp, P-gp function and expression were investigated in hepatoma cell lines Huh-7 and HepG2 and in primary hepatocyte-derived HuS-E/2 cells. At a subtoxic concentration, 48-h exposure to 7-KC reduced the intracellular accumulation and cytotoxicity of P-gp substrate doxorubicin in hepatoma cells, but not in HuS-E/2 cells. In Huh-7 cells, 7-KC elevated efflux function through the activation of phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway. 7-KC activated the downstream protein synthesis initiation factor 4E-BP1 and induced P-gp expression post-transcriptionally. The stimulation of efflux was reversible and could not be prevented by N-acetyl cysteine. Total cellular ATP content remained the same, whereas the lactate production was increased and fluorescence lifetime of protein-bound NADH was shortened. These changes suggested a metabolic shift to glycolysis, but glycolytic inhibitors did not eliminate 7-KC-mediated P-gp induction. These results demonstrate that 7-KC induces P-gp through PI3K/mTOR signaling and decreased the cell-killing efficacy of doxorubicin in hepatoma cells.

Keywords: 3-(4,5-dimethyl-thiazol-2yl)-2,5-diphenyl tetrazolium; 4E-BP1; 7-KC; 7-Ketocholesterol; 7-ketocholesterol; AKI; Akt kinase inhibitor; ERK; FBS; FLIM; GAPDH; Glycolysis; Hepatoma; LDH; MDR; MTT; NADH; P-Glycoprotein; P-glycoprotein; P-gp; PBMC; PCR; PI3K; PI3K/mTOR; ROS; RT; Rh123; eukaryotic translation initiation factor (eIF) 4E-binding protein 1; extracellular signal-regulated kinase; fetal bovine serum; fluorescence lifetime imaging; glyceraldehyde 3-phosphate dehydrogenase; lactate dehydrogenase; mTOR; mammalian target of rapamycin; multidrug resistance; p70 ribosomal protein S6 kinase; p70S6K; peripheral blood mononuclear cells; phosphatidylinositol 3-kinase; polymerase chain reaction; reactive oxygen species; reduced nicotinamide adenine dinucleotide; reverse transcription; rhodamine 123.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / biosynthesis*
  • Acetylcysteine / pharmacology
  • Antibiotics, Antineoplastic / metabolism
  • Antibiotics, Antineoplastic / pharmacology
  • Antioxidants / pharmacology
  • Carcinoma, Hepatocellular
  • Cell Line
  • Cell Line, Tumor
  • Cell Survival
  • Cholesterol / pharmacology
  • Doxorubicin / metabolism
  • Doxorubicin / pharmacology
  • Drug Resistance, Neoplasm
  • Hepatocytes / metabolism
  • Humans
  • Hydroxycholesterols / pharmacology
  • Ketocholesterols / metabolism
  • Ketocholesterols / pharmacology*
  • Lactic Acid / biosynthesis
  • Oligomycins / pharmacology
  • Phosphatidylinositol 3-Kinases / metabolism*
  • Phosphoinositide-3 Kinase Inhibitors
  • Signal Transduction
  • TOR Serine-Threonine Kinases / antagonists & inhibitors
  • TOR Serine-Threonine Kinases / metabolism*
  • Up-Regulation

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Antibiotics, Antineoplastic
  • Antioxidants
  • Hydroxycholesterols
  • Ketocholesterols
  • Oligomycins
  • Phosphoinositide-3 Kinase Inhibitors
  • Lactic Acid
  • cholest-5-en-3 beta,7 alpha-diol
  • Doxorubicin
  • Cholesterol
  • TOR Serine-Threonine Kinases
  • 7-ketocholesterol
  • Acetylcysteine